相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era
M. Marin et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
Hisham Mehanna et al.
LANCET (2019)
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Maura L. Gillison et al.
LANCET (2019)
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
R. I. Haddad et al.
ANNALS OF ONCOLOGY (2018)
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer
Sana D. Karam et al.
CLINICAL CANCER RESEARCH (2018)
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial
Yungan Tao et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NCCN Guidelines® Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines
A. Dimitrios Colevas et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Double positivity for HPV-DNA/p16(ink4a) is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients
Marisa Mena et al.
ORAL ONCOLOGY (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial
Robert L. Ferris et al.
JAMA ONCOLOGY (2018)
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
Tomohiro Enokida et al.
FRONTIERS IN ONCOLOGY (2018)
Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
Pierluigi Bonomo et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2018)
A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck
Stephen G. Chun et al.
CANCER INVESTIGATION (2017)
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Laura Q. M. Chow et al.
CLINICAL CANCER RESEARCH (2017)
Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis
Elena-Sophie Prigge et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer
Michela Buglione et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study
Ricard Mesia et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx-ECOG-ACRIN Cancer Research Group
Shanthi Marur et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
p16, HPV, and Cetuximab: What Is the Evidence?
James A. Bonner et al.
ONCOLOGIST (2017)
Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status
Dan Ou et al.
ORAL ONCOLOGY (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma A Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2017)
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Athanassios Argiris et al.
FRONTIERS IN ONCOLOGY (2017)
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
P. Bossi et al.
ANNALS OF ONCOLOGY (2017)
Human papillomavirus-related oropharyngeal cancer
M. Taberna et al.
ANNALS OF ONCOLOGY (2017)
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial
P. M. Specenier et al.
ANNALS OF ONCOLOGY (2017)
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy
Laura Lattanzio et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Phase II trial of bevacizumab plus cetuximab plus cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma
Matthew G. Fury et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck
Nadeem Riaz et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial)
M. Hecht et al.
ANNALS OF ONCOLOGY (2016)
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
J. Bauman et al.
ANNALS OF ONCOLOGY (2016)
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck canceraEuro
A. Argiris et al.
ANNALS OF ONCOLOGY (2016)
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
Jingwen Huang et al.
BMC CANCER (2016)
Treatment de-intensification strategies for head and neck cancer
Jacqueline R. Kelly et al.
EUROPEAN JOURNAL OF CANCER (2016)
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck
Ricard Mesia et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma
Lori J. Wirth
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab
David I. Rosenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial
Stefano Maria Magrini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review
Myung-Ju Ahn et al.
ORAL ONCOLOGY (2016)
Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck
Jenniffer Linares et al.
ORAL ONCOLOGY (2016)
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Jerome Fayette et al.
FRONTIERS IN ONCOLOGY (2016)
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
J. Guigay et al.
ANNALS OF ONCOLOGY (2015)
Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetwdmab: A systematic review and meta-analysis
Omar Abdel-Rahman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
Maura L. Gillison et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial
Jordi Giralt et al.
LANCET ONCOLOGY (2015)
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
Ricard Mesia et al.
LANCET ONCOLOGY (2015)
Late toxicity after radical treatment for locally advanced head and neck cancer
Miren Taberna et al.
ORAL ONCOLOGY (2015)
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno et al.
ORAL ONCOLOGY (2015)
Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis
Lijuan Zhang et al.
SCIENTIFIC REPORTS (2015)
Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Michaela K. Keck et al.
CLINICAL CANCER RESEARCH (2015)
Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Tanguy Y. Seiwert et al.
CLINICAL CANCER RESEARCH (2015)
Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
Prakash Peddi et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
A phase I (Ph1) study of dasatinib (D) with cetuximab (Cet) /radiation (IMRT) plus /- cisplatin (P) in stage II, III/IV head and neck squamous cell carcinoma (HNSCC).
Shanthi Marur et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
R. Hitt et al.
ANNALS OF ONCOLOGY (2014)
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
J. B. Vermorken et al.
ANNALS OF ONCOLOGY (2014)
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
J. B. Vermorken et al.
ANNALS OF ONCOLOGY (2014)
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
T. Y. Seiwert et al.
ANNALS OF ONCOLOGY (2014)
Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
M. Baro et al.
BRITISH JOURNAL OF CANCER (2014)
Phase 1 and Pharmacokinetic Study of Everolimus in Combination With Cetuximab and Carboplatin for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Nabil F. Saba et al.
CANCER (2014)
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer
Angelica Nogueira-Rodrigues et al.
CANCER (2014)
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck
Primoz Strojan et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234
Paul M. Harari et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors
Michelle M. Rietbergen et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2014)
Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis of published studies
Fausto Petrelli et al.
ORAL ONCOLOGY (2014)
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients
B. K. M. Reddy et al.
ORAL ONCOLOGY (2014)
The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines
Julian David Guster et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial
Jan Baptist Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A. Argiris et al.
ANNALS OF ONCOLOGY (2013)
Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients
Jerome Fayette et al.
ANTI-CANCER DRUGS (2013)
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer
Bella Pajares et al.
BMC CANCER (2013)
Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence
Gianmauro Numico et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
J. B. Vermorken et al.
EUROPEAN JOURNAL OF CANCER (2013)
Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab
Allison Y. Ye et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2013)
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
Jean Louis Lefebvre et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B. Vermorken et al.
LANCET ONCOLOGY (2013)
Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie
M. Knoedler et al.
ONCOLOGY (2013)
Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Jessica Ley et al.
ONCOLOGY (2013)
Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma
Jesse D. Troy et al.
HEAD & NECK PATHOLOGY (2013)
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
R. Hitt et al.
ANNALS OF ONCOLOGY (2012)
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer
Susan Urba et al.
CANCER (2012)
Zalutumumab in head and neck cancer
Ulrike Schick et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Mark Agulnik
MEDICAL ONCOLOGY (2012)
Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature
Guilherme Rabinowits et al.
ORAL ONCOLOGY (2012)
Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study
M. Merlano et al.
ANNALS OF ONCOLOGY (2011)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Steve C. Lee et al.
IMMUNOLOGIC RESEARCH (2011)
CONCURRENT CISPLATIN AND RADIATION VERSUS CETUXIMAB AND RADIATION FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER
Lawrence Koutcher et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
Jochen H. Lorch et al.
LANCET ONCOLOGY (2011)
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer
Athanassios Argiris et al.
ORAL ONCOLOGY (2011)
Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
Somaira Nowsheen et al.
PLOS ONE (2011)
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
V. Gregoire et al.
ANNALS OF ONCOLOGY (2010)
Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial
Merrill S. Kies et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
Danny Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix A Gynecologic Oncology Group Study
Russell J. Schilder et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Effects of chemoradiation on tumor-host interactions: The immunologic side
Silvia C. Formenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer
Bhavna Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer
Andres Upez-Albaitero et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2007)
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
Hideharu Kimura et al.
CANCER SCIENCE (2007)
Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer
Niklas Reimers et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents
Josep Tabernero
MOLECULAR CANCER RESEARCH (2007)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Jean Bourhis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma?
AS Garden et al.
CANCER (2004)
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines
LH Kalish et al.
CLINICAL CANCER RESEARCH (2004)
Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts
WC Rose et al.
CLINICAL CANCER RESEARCH (2004)
Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
PM Harari et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
分享论文
